Az Izraeli lapok vezércikkeiből angolul

The Jerusalem Post reflects on the passing of Rabbi Aharon Lichtenstein, one of the most influential and original thinkers of modern Orthodoxy, and notes that while his death is a major loss for Orthodoxy and for Israeli society, “his legacy, which provides a deeper understanding of Independence Day and the meaning of Jewish sovereignty, lives on in his many students and admirers.”

Haaretz attacks PM Netanyahu’s promotion of changes in status to the Supreme Court, which directly contradict the vow he made two months ago when he promised not to seek such changes, and asserts: “Implementing the prime minister’s proposed changes would undermine the tenets of Israel’s democratic nature.”

Yediot Aharonot declares: “On the Day of Remembrance for the Fallen Soldiers of Israel and Victims of Terrorism, all the fatalities – from the very first of the pioneers who came to Mandatory Palestine, and through to the most recent, today or tomorrow, whose name we don’t even know yet – were our own sons and daughters.” The author notes that while there is hardly a more moving and emotional moment than the one experienced by parents as their sons and daughters get onto the bus at the IDF recruitment center, most will return home some three years later. The author adds that those who do not return, those for whom it is a one-way journey, “They are the ones we remember tonight and tomorrow.”

Yisrael Hayom comments that while “Israel is the only country in the world whose right to exist and defend itself is continuously ‎challenged,” nevertheless, “by any benchmark Israel unquestionably represents the greatest national ‎success story of all time.‎” The author adds: “Today, on our 67th anniversary, we should give thanks to the Almighty for enabling us to be ‎the blessed Jewish generation, privileged to live in freedom in our resurrected ancient ‎homeland,” and concludes: “We should continually remind ourselves that our success defies rationality and by ‎any benchmark must be deemed miraculous.‎”

Globes believes that Israel pharmaceutical giant Teva is taking a great risk in bidding for Mylan, a global generic and specialty pharmaceuticals company headquartered in Pennsylvania, because in order to do so Teva will not only “need to significantly increase its debt (and possibly even suffer a downgrading of its debt rating),” it will also “need to absorb a huge company with 30,000 employees and dozens of production sites.” The author declares that even though “The market received Teva’s offer positively,” nevertheless “The burden of proof is on Teva.”